Current and novel therapeutic opportunities for systemic therapy in biliary cancer
José J.G. Marı́n(Universidad de Salamanca), Adelaida La Casta(Institut Català d'Oncologia), Marco Marzioni(Marche Polytechnic University), Pedro M. Rodrigues(Ikerbasque), Chiara Braconi(Beatson West of Scotland Cancer Centre), Simona Tavolari(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Rocı́o I.R. Macı́as(Universidad de Salamanca), Ana Ruivo(Hospitais da Universidade de Coimbra), Pilar Acedo(University College London), Giulia Mentrasti(Marche Polytechnic University), Ana Landa-Magdalena(Clinica Universidad de Navarra), Giovanni Brandi(Hôpital Beaujon), Oreste Segatto, Juan W. Valle(Cancer Research UK Manchester Institute), Vincenzo Cardinale(Erasmus MC), Arndt Vogel(Princess Margaret Cancer Centre), Maite G. Fernández‐Barrena(Instituto de Salud Carlos III), Patricia Muñoz-Garrido, John Bridgewater(University College London Hospitals NHS Foundation Trust), Jesús M. Bañales(University of the Basque Country), Ángela Lamarca(Hospital Universitario Fundación Jiménez Díaz), Maria Giuseppina Prete(Humanitas University), Cecília M. P. Rodrigues(University of Lisbon), Joachim C. Mertens(GastroZentrum Hirslanden Zürich)
Cited by 61
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k